Table of Contents
This BCC Research report reviews the status of next generation cancer diagnostic technologies and assays, and assesses their global growth potential over a five-year period from 2014 to 2019. Influencing factors, including cancer diagnostic needs, regulatory trends, industry structure and patent status are also discussed.
Use this report to:
- Review the status of next generation cancer diagnostic technologies and assays, and assess their global growth potential over a five-year period from 2014 to 2019.
- Analyze the key trends, markets and industry dynamics to provide a useful basis for corporate decision making.
- Study the market analysis and forecast from 2014 through 2019 by cancer indication, analysis type performed and diagnostic function.
- Gain insight into innovative technology platforms that provide more sensitive, accurate and rapid diagnostic tools for oncologists to use when treating cancer patients.
- BCC Research estimates the global market for next generation cancer diagnostic as $1.6 billion in 2013. This indication is expected to reach $1.8 billion in 2014 and $10 billion
in 2019, registering a compound annual growth (CAGR) of 42.6% over the next five years.
- Solid tumors, excluding sex-related tumors as a segment will grow from $742.9 million in 2014 to nearly $4.6 billion by 2019 at a 44% CAGR for the period 2014-2019.
- Blood-born cancers is the largest segment of the global market for next generation cancer diagnostic and it is expected to reach $140.2 million in 2014 and $1.4 billion by 2019, increasing at a CAGR of 60.2% from 2014 through 2019.
STUDY GOALS AND OBJECTIVES
The objective of this study is to review the status of next generation cancer diagnostic technologies and assays, and assess their global growth potential over a five-year period from 2014 to 2019. Particularly focus is placed on characterizing the markets for the key next generation platforms: real-time polymerase chain reaction (RT-PCR), DNA
microarrays, lab-on-a-chip (LOAC), protein microarrays, next generation capture methods (e.g., circulating tumor cells, exosomes, cell-free DNA/RNA), multiplexed conventional and next generation sequencing (NGS). A main focus of this report is genomic, epigenomic, proteomic and cellular analysis, in which the majority of cancer diagnostic sales occur. The main objective is to present a comprehensive review of next generation platforms by cancer indication to assess the industry’s future market potential.
REASONS FOR DOING THE STUDY
Cancer is a collection of diseases caused by genetic malfunctions. The ongoing discovery of new genomic and proteomic information since the completion of the Human Genome Project is leading to the discovery of new disease biomarkers. These biomarkers can be correlated with cancer initiation and progression. There has also been tremendous scientific progress in novel analysis technologies, including LOAC, RT-PCR, high-density microarrays, NGS, cellular capture and identification and multiplexed assays. These technological forces are merging with unmet cancer diagnostic needs to create favorable conditions for future commercial growth. Thus, it is particularly timely to review the market opportunities and future growth of specific cancer diagnostic market segments.
The next generation cancer diagnostic industry is a relatively small but growing segment of the in vitro diagnostic industry. Some tests are already established, including in cervical cancer screening, colorectal cancer and breast cancer prognostics. A significant number of new assays using innovative platforms are in the diagnostic pipeline. Companies seeking to exploit the growth in this industry must understand the various next generation platforms and their development status for each cancer indication.
Given the emerging nature of this industry, it is timely to analyze the key trends, markets and industry dynamics to provide a useful basis for corporate decision making.
BCC Research has compiled a study of the main next generation platforms that will be important in key end-user segments. These cancer diagnostic markets are analyzed by
indication (e.g., breast, colorectal, prostate), type of analysis (e.g., gene expression, genotyping, cytogenetic), technology platform (e.g., NGS, LOAC, DNA microarray), and
diagnostic function (e.g., screening/early detection, prognosis, monitoring/recurrence, companion diagnostic). This report examines the next generation diagnostic technologies, forces driving industry growth, product types, key market applications, companies, corporate alliances, future market potential and global markets for the period 2013 through 2019. It analyzes industry dynamics, including each of the distinct industry subsegments, as well as recent corporate acquisitions and alliances.
This study will be of particular interest to companies in:
- In vitro diagnostics.
- Life sciences tools and reagents.
- Medical devices.
- DNA sequencing.
- DNA microarrays.
- Protein microarrays.
- Clinical laboratories.
SCOPE AND FORMAT
The study scope includes the major next generation formats that are likely to become commercialized within the next five years. Each technology format is analyzed to
determine its market status, impact on future market segments and projected growth from 2014 through 2019. Technology issues and forces driving the market are discussed.
Influencing factors, including cancer diagnostic needs, regulatory trends, industry structure and patent status are also discussed. BCC Research examines companies in the industry, corporate alliances and assay consumption by indication. More than 130 companies participating in the industry are profiled in this report.
BCC Research presents an analysis of each of the key market segments that will be commercially important during the next five years: RT-PCR, DNA microarrays, protein
microarrays, LOAC, next generation capture, NGS, and multiplexed conventional. Based on this analysis, potential applications of next generation platforms in each of the major market segments and their forecast market value for 2014 through 2019 will be evaluated. For each technology platform, this report provides a market analysis and forecast from 2014 through 2019 by cancer indication, analysis type performed and diagnostic function. For each analysis type (e.g., detection, early screening), the market size by cancer indication is forecast. For selected key cancer indications, a detailed forecast of the next generation technology formats is provided. Finally, the overall next generation cancer diagnostic market by geographical region is provided.
Both primary and secondary information sources were used in preparing this study. BCC Research surveyed life science companies and research institutions to obtain data
for this study. Research tools, diagnostics, drug firms, and leading research institutions were included. In addition, data from secondary sources, including industry, trade and
government organizations, were used.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected ...
Use this report to: - Analyze the global prostate cancer market, with important statistics and analysis on existing drugs, and diagnostic technologies. - Receive information on regulatory environment, ...
Complete report $9,800. DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...